Carter 1975.
Study characteristics | ||
Methods | Phase III parallel‐group RCT. Open label study. |
|
Participants | Untreated and previously treated metastatic melanoma. Number of participants:270. |
|
Interventions | Four‐arm trial:
|
|
Outcomes | Progression‐free survival. Overall survival. Tumour response. Toxicity. |
|
Notes | Cross‐over: not allowed. Quality of life: not reported. Participants with brain metastasis: included. Median follow‐up: not available. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Quote: "Patients were randomised". Comment: There was insufficient information to permit judgment. |
Allocation concealment (selection bias) | Unclear risk | There was insufficient information to permit judgment. |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | As an open label study, no blinding of participants or personnel was possible. However, we believe that in this setting (metastatic melanoma), with the treatments tested and outcomes assessed, the knowledge of which intervention was received or administered (rather than the intervention itself), could not affect the outcomes under investigation. Therefore, we judged the risk of performance bias as low. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | There was insufficient information to permit judgment. |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | There was insufficient information to permit judgment. |
Selective reporting (reporting bias) | Unclear risk | There was insufficient information to permit judgment. |
Other bias | Unclear risk | There was insufficient information to permit judgment. |